1. Delgado-López PD, Corrales-García EM. Survival in glioblastoma: a review on the impact of treatment modalities. Clin Transl Oncol 2016; 18(11): 1062-71.

2. Pessina F, Navarria P, Cozzi L, Ascolese AM, Simonelli M, Santoro A, et al. Maximize surgical resection beyond contrast-enhancing boundaries in newly diagnosed glioblastoma multiforme: is it useful and safe? A single institution retrospective experience. J Neurooncol 2017; 135(1): 129-39.

3. Ahmadi-Beni R, Khoshnevisan A. An overview of crucial genes involved in stemness of glioblastoma multiforme. Neurochem J 2017; 11(4): 259-65.

4. Ahmadi-Beni R, Najafi A, Savar SM, Mohebbi N, Khoshnevisan A. Role of dimethyl fumarate in the treatment of glioblastoma multiforme: A review article. Iran J Neurol 2019;18(3):127.

5. Noori-Daloii M-R, Ahmadi-beni R. Glioblastoma gene therapy and related delivery systems. Med Sci 2017; 27(3): 149-63. [in Persian]

6. Garlanda C, Bottazzi B, Magrini E, Inforzato A, Mantovani A. PTX3, a humoral pattern recognition molecule, in innate immunity, tissue repair, and cancer. Physiol Rev 2018; 98(2): 623-39.

7. Wang Z, Wang X, Zou H, Dai Z, Feng S, Zhang M, et al. The Basic Characteristics of the Pentraxin Family and Their Functions in Tumor Progression. Front Immunol 2020; 11: 1757.

8. Giacomini A, Ghedini GC, Presta M, Ronca R. Long pentraxin 3: A novel multifaceted player in cancer. Biochim Biophys Acta Rev Cancer 2018; 1869(1): 53-63.

9. Doni A, Stravalaci M, Inforzato A, Magrini E, Mantovani A, Garlanda C, et al. The long pentraxin PTX3 as a link between innate immunity, tissue remodeling, and cancer. Front Immunol 2019; 10: 712.

10. Wang Z, Wang X, Zhang N, Zhang H, Dai Z, Zhang M, et al. Pentraxin 3 promotes glioblastoma progression by negative regulating cells autophagy. Front Cell Dev Biol 2020; 8: 795.

11. Petterson SA, Sørensen MD, Kristensen BW. Expression profiling of primary and recurrent glioblastomas reveals a reduced level of pentraxin 3 in recurrent glioblastomas. J Neuropathol Exp Neurol 2020; 79(9): 975-85.

12. Locatelli M, Ferrero S, Boneschi FM, Boiocchi L, Zavanone M, Gaini SM, et al. The long pentraxin PTX3 as a correlate of cancer-related inflammation and prognosis of malignancy in gliomas. J Neuroimmunol 2013; 260(1-2): 99-106.

13. Yeh CM, Lin CW, Chuang CY, Liu YF, Chou CH, Yang SF, et al. Functional genetic variant of long PENTRAXIN 3 gene is associated With clinical aspects of oral cancer in male patients. Front Oncol 2019; 9: 581.

14. Gluszek S, Matykiewicz J, Grabowska U, Chrapek M, Nawacki L, Wawrzycka I, et al. Clinical usefulness of pentraxin 3 (PTX3) as a biomarker of acute pancreatitis and pancreatic cancer. Stud Med 2020; 36(1): 6-13.

15. Goulart MR, Watt J, Siddiqui I, Lawlor RT, Imrali A, Hughes C, et al. Pentraxin 3 is a stromally-derived biomarker for detection of pancreatic ductal adenocarcinoma. NPJ Precis Oncol 2021; 5(1): 1-10.

16. Choi B, Lee E-J, Shin M-K, Park YS, Ryu M-H, Kim S-M, et al. Upregulation of brain-derived neurotrophic factor in advanced gastric cancer contributes to bone metastatic osteolysis by inducing long pentraxin 3. Oncotarget 2016; 7(34): 55506.

17. Choi B, Lee EJ, Park YS, Kim S-M, Kim EY, Song Y, et al. Pentraxin-3 silencing suppresses gastric cancer-related inflammation by inhibiting chemotactic migration of macrophages. Anticancer Res 2015; 35(5): 2663-8.

18. Hu T, Qiao L, Li H, Ren H, Ning Q, Zhou H, et al. Pentraxin 3 (PTX-3) Levels in Bronchoalveolar Lavage Fluid as a Lung Cancer Biomarker. Dis Markers 2020; 2020.

19. Ahmmed B, Kampo S, Khan M, Faqeer A, Kumar SP, Yulin L, et al. Rg3 inhibits gemcitabine‐induced lung cancer cell invasiveness through ROS‐dependent, NF‐κB‐and HIF‐1α‐mediated downregulation of PTX3. J Cell Physiol 2019; 234(7): 10680-97.

20. Ying TH, Lee CH, Chiou HL, Yang SF, Lin CL, Hung CH, et al. Knockdown of Pentraxin 3 suppresses tumorigenicity and metastasis of human cervical cancer cells. Sci Rep 2016; 6(1): 1-12.

21. Yu LM, Wang WW, Qi R, Leng TG, Zhang XL. MicroRNA‐224 inhibition prevents progression of cervical carcinoma by targeting PTX3. J Cell Biochem 2018; 119(12): 10278-90.

22. Kampo S, Ahmmed B, Zhou T, Owusu L, Anabah TW, Doudou NR, et al. Scorpion venom analgesic peptide, BmK AGAP inhibits stemness, and epithelial-mesenchymal transition by down-regulating PTX3 in breast cancer. Front Oncol 2019; 9: 21.

23. Zhang P, Liu Y, Lian C, Cao X, Wang Y, Li X, et al. SH3RF3 promotes breast cancer stem-like properties via JNK activation and PTX3 upregulation. Nat Commun 2020;11(1):1-13.

24. Wills CA, Liu X, Chen L, Zhao Y, Dower CM, Sundstrom J, et al. Chemotherapy-induced upregulation of small extracellular vesicle-associated PTX3 accelerates breast cancer metastasis. Cancer Res 2021;81(2):452-63.

25. Chang X, Li D, Liu C, Zhang Z, Wang T. Pentraxin 3 is a diagnostic and prognostic marker for ovarian epithelial cancer patients based on comprehensive bioinformatics and experiments. Cancer Cell Int 2021; 21(1): 1-13.

26. Stallone G, Netti GS, Cormio L, Castellano G, Infante B, Pontrelli P, et al. Modulation of complement activation by pentraxin-3 in prostate cancer. Sci Rep 2020; 10(1): 1-11.

27. Güzel Ö, Kösem A, Aslan Y, Asfuroglu A, Balci M, Senel C, et al. The Role of Pentraxin-3, Fetuin-A and Sirtuin-7 in the Diagnosis of Prostate Cancer. Urol J 2021: 6626.

28. Falagario UG, Busetto GM, Netti GS, Sanguedolce F, Selvaggio O, Infante B, et al. Prospective Validation of Pentraxin-3 as a Novel Serum Biomarker to Predict the Risk of Prostate Cancer in Patients Scheduled for Prostate Biopsy. Cancers (Basel) 2021; 13(7): 1611.

29. Netti GS, Lucarelli G, Spadaccino F, Castellano G, Gigante M, Divella C, et al. PTX3 modulates the immunoflogosis in tumor microenvironment and is a prognostic factor for patients with clear cell renal cell carcinoma. Aging (Albany NY) 2020; 12(8): 7585.

30. Liu B, Zhao Y, Guo L. Increased serum pentraxin-3 level predicts poor prognosis in patients with colorectal cancer after curative surgery, a cohort study. Medicine (Baltimore) 2018;97(40).

31. Deng H, Fan X, Wang X, Zeng L, Zhang K, Zhang X, et al. Serum pentraxin 3 as a biomarker of hepatocellular carcinoma in chronic hepatitis B virus infection. Sci Rep 2020;10(1):1-10.

32. Cabiati M, Gaggini M, De Simone P, Del Ry S. Do pentraxin 3 and neural pentraxin 2 have different facet function in hepatocellular carcinoma? Clin Exp Med 2021:1-8.

33. Carmo RF, Aroucha D, Vasconcelos LRS, Pereira L, Moura P, Cavalcanti MSM. Genetic variation in PTX 3 and plasma levels associated with hepatocellular carcinoma in patients with HCV. J Viral Hepat 2016;23(2):116-22.

34. Rathore M, Girard C, Ohanna M, Tichet M, Jouira RB, Garcia E, et al. Cancer cell-derived long pentraxin 3 (PTX3) promotes melanoma migration through a toll-like receptor 4 (TLR4)/NF-κB signaling pathway. Oncogene 2019; 38(30): 5873-89.

35. Guo P, Zhang SZ, He H, Zhu Y-T, Tseng SCG. PTX3 controls activation of matrix metalloproteinase 1 and apoptosis in conjunctivochalasis fibroblasts. Invest Ophthalmol Vis Sci 2012; 53(7): 3414-23.

36. Lee HH, Kim SY, Na JC, Yoon YE, Han WK. Exogenous pentraxin-3 inhibits the reactive oxygen species-mitochondrial and apoptosis pathway in acute kidney injury. PloS One 2018; 13(4): e0195758.

37. Lian C, Huang Q, Zhong X, He Z, Liu B, Zeng H, et al. Pentraxin 3 secreted by human adipose‐derived stem cells promotes dopaminergic neuron repair in Parkinson's disease via the inhibition of apoptosis. FASEB J 2021;35(7):e21748.

38. He D, Yan L. MiR-29b-3p aggravates cardiac hypoxia/reoxygenation injury via targeting PTX3. Cytotechnology 2021; 1-10.

39. Chang WC, Wu SL, Huang WC, Hsu JY, Chan SH, Wang JM, et al. PTX3 gene activation in EGF-induced head and neck cancer cell metastasis. Oncotarget 2015; 6(10): 7741.

40. Ahmmed B, Khan MN, Nisar MA, Kampo S, Zheng Q, Li Y, et al. Tunicamycin enhances the suppressive effects of cisplatin on lung cancer growth through PTX3 glycosylation via AKT/NF-κB signaling pathway. Int J Oncol 2019; 54(2): 431-42.

41. Chan SH, Tsai JP, Shen CJ, Liao YH, Chen BK. Oleate-induced PTX3 promotes head and neck squamous cell carcinoma metastasis through the up-regulation of vimentin. Oncotarget 2017; 8(25): 41364.

42. Thomas C, Henry W, Cuiffo BG, Collmann AY, Marangoni E, Benhamo V, et al. Pentraxin-3 is a PI3K signaling target that promotes stem cell–like traits in basal-like breast cancers. Sci Signal 2017; 10(467).

43. O’Keefe EP. siRNAs and shRNAs: Tools for protein knockdown by gene silencing. Mater Methods 2013; 3: 197.

44. Jinek M, Doudna JA. A three-dimensional view of the molecular machinery of RNA interference. Nature 2009; 457(7228): 405-12.

45. Paddison PJ, Caudy AA, Bernstein E, Hannon GJ, Conklin DS. Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells. Genes Dev 2002; 16(8): 948-58.

46. Malekshahi SS, Arefian E, Salimi V, Azad TM, Yavarian J. Potential siRNA molecules for nucleoprotein and M2/L overlapping region of respiratory syncytial virus: In silico design. Jundishapur J Microbiol 2016; 9(4).

47. Tuschl T. Tom Tuschl's motif siRNA design rules and siRNA rational design. Protocol Online 2009. Available at: http://www.protocol-online.org/prot/Protocols/Rules-of-siRNA-design-for-RNA-interference--RNAi--3210.html

48. Baghban-Kohnehrouz B, Nayeri S. Design, simplified cloning, and in-silico analysis of multisite small interfering RNA-targeting cassettes. Mol Biol Res Commun 2016; 5(1): 31.

49. McIntyre GJ, Yu YH, Lomas M, Fanning GC. The effects of stem length and core placement on shRNA activity. BMC Mol Biol 2011; 12(1): 1-12.

50. Bofill-De Ros X, Gu S. Guidelines for the optimal design of miRNA-based shRNAs. Methods 2016; 103: 157-66.

51. Fakhr E, Zare F, Teimoori-Toolabi L. Precise and efficient siRNA design: a key point in competent gene silencing. Cancer Gene Ther 2016; 23(4): 73-82.

52. Tung JN, Ko CP, Yang SF, Cheng CW, Chen P-N, Chang CY, et al. Inhibition of pentraxin 3 in glioma cells impairs proliferation and invasion in vitro and in vivo. J Neurooncol 2016;129(2):201-9.

53. Liu Q, Wang XY, Qin YY, Yan XL, Chen HM, Huang QD, et al. SPOCD1 promotes the proliferation and metastasis of glioma cells by up-regulating PTX3. Am J Cancer Res 2018;8(4):624.

54. Ke HH, Hueng DY, Tsai WC. Low expression of pentraxin 3 and nuclear factor-like 2 implying a relatively longer overall survival time in gliomas. Chin J Physiol 2019; 62(1): 35.

55. Li Y, Song X, Niu J, Ren M, Tang G, Sun Z, et al. Pentraxin 3 acts as a functional effector of Akt/NF-κB signaling to modulate the progression and cisplatin-resistance in non-small cell lung cancer. Arch Biochem Biophys 2021; 701: 108818.